New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol

Drug Des Devel Ther. 2013 Oct 10;7:1201-8. doi: 10.2147/DDDT.S39449. eCollection 2013.


An increasing body of evidence suggests that the long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combination appears to play an important role in maximizing bronchodilation, with studies to date indicating that combining different classes of bronchodilators may result in significantly greater improvements in lung function compared to the use of a single drug, and that these combinations are well tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). An inhaled, fixed-dose combination of two 24-hour bronchodilators, the LAMA umeclidinium and the LABA vilanterol, is under development as a once-daily treatment for COPD. The efficacy of both mono-components has already been demonstrated. The information currently available suggests that umeclidinium/vilanterol is an effective once-daily dual bronchodilator fixed-dose combination in the treatment of COPD. However, it remains to be seen if it compares favorably with current therapies. Moreover, the question remains whether umeclidinium/vilanterol fixed-dose combination, which significantly improves FEV1, is also associated with improvements in other outcome measures that are important to COPD patients.

Keywords: COPD; dual bronchodilation; muscarinic antagonist.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Adrenergic beta-2 Receptor Agonists / administration & dosage
  • Adrenergic beta-2 Receptor Agonists / pharmacology
  • Adrenergic beta-2 Receptor Agonists / therapeutic use
  • Benzyl Alcohols / administration & dosage
  • Benzyl Alcohols / pharmacology
  • Benzyl Alcohols / therapeutic use*
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / pharmacology
  • Bronchodilator Agents / therapeutic use
  • Chlorobenzenes / administration & dosage
  • Chlorobenzenes / pharmacology
  • Chlorobenzenes / therapeutic use*
  • Delayed-Action Preparations
  • Drug Combinations
  • Forced Expiratory Volume
  • Humans
  • Muscarinic Antagonists / administration & dosage
  • Muscarinic Antagonists / pharmacology
  • Muscarinic Antagonists / therapeutic use
  • Outcome Assessment, Health Care
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Quinuclidines / administration & dosage
  • Quinuclidines / pharmacology
  • Quinuclidines / therapeutic use*


  • Adrenergic beta-2 Receptor Agonists
  • Benzyl Alcohols
  • Bronchodilator Agents
  • Chlorobenzenes
  • Delayed-Action Preparations
  • Drug Combinations
  • GSK573719
  • Muscarinic Antagonists
  • Quinuclidines
  • vilanterol